This site is intended for U.S. healthcare professionals.

Visit Pfizer MedicalVisit Pfizer MedicalLoading

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient ProfilesPatient
ProfilesIdentifying PatientsUnmet NeedsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
HYMPAVZI injection overviewHYMPAVZI injection overview

Learn how to use the HYMPAVZI prefilled pen.1 Watch the full Instructions for Use video.

Learn how to use the HYMPAVZI prefilled pen.1 Watch the full Instructions for Use video.

  • Start by inspecting the package and the expiration date
    Make sure there is no damage to the pen and that today’s date is not past the expiration date. Look at the medicine through the window; it should be clear and colorless to light yellow. Do not use if it is cloudy, dark yellow, or contains flakes or particles.
  • Next, choose and clean the injection site
    HYMPAVZI may be injected into the abdomen or thigh (or into the buttocks by a healthcare provider or caregiver). Rotate injection sites each week.
  • Then, twist and pull off the cap
    The needle cover will stay inside the cap after cap removal. It is normal to see a few drops of medicine at the tip of the needle. Do not put hands over the needle guard; doing so may cause injury.
  • To inject, push straight down until there’s a click.
    The click indicates that the injection has started. After the click, continue pushing the pen down firmly against the skin.
  • After the second click, count to 5
    Keeping the pen against the skin, look for a yellow bar to completely fill the window. There will be a second click when the injection is almost complete. Count slowly to 5 after hearing the second click and then remove the pen carefully from the skin.
  • Finished
    Dispose of the entire pen in a sharps container.
  • Start by inspecting the package and the expiration date

Make sure there is no damage to the pen and that today’s date is not past the expiration date. Look at the medicine through the window; it should be clear and colorless to light yellow. Do not use if it is cloudy, dark yellow, or contains flakes or particles.

  • Next, choose and clean the injection site

HYMPAVZI may be injected into the abdomen or thigh (or into the buttocks by a healthcare provider or caregiver). Rotate injection sites each week.

  • Then, twist and pull off the cap
The needle cover will stay inside the cap after cap removal. It is normal to see a few drops of medicine at the tip of the needle. Do not put hands over the needle guard; doing so may cause injury.
  • To inject, push straight down until there’s a click
The click indicates that the injection has started. After the click, continue pushing the pen down firmly against the skin.
  • After the second click, count to 5
Keeping the pen against the skin, look for a yellow bar to completely fill the window. There will be a second click when the injection is almost complete. Count slowly to 5 after hearing the second click and then remove the pen carefully from the skin.
  • Finished
Dispose of the entire pen in a sharps container.

HYMPAVZI is intended for use under the guidance of a healthcare provider. After proper training in subcutaneous injection technique, a patient may self-inject or the patient’s caregiver may administer HYMPAVZI, if a healthcare provider determines that it is appropriate.1​​​​​​​

 Who is the right patient for HYMPAVZI?

Find out if you have patients who could be eligible for HYMPAVZI

 Identify eligible patients LoadingReference:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2024. Dosing & AdminDosing & AdminHYMPAVZI is a trademark of Pfizer Inc.HYMPAVZI is a trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-HYM-USA-0073
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
 
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.